NCT01244763 is a Phase 2 clinical trial of Roxadustat in Chronic Kidney Disease, sponsored by Kyntra Bio.

Who is sponsoring NCT01244763?

NCT01244763 is sponsored by Kyntra Bio.

What drugs are being tested in NCT01244763?

Interventions in NCT01244763: Roxadustat.

What condition does NCT01244763 study?

NCT01244763 studies Chronic Kidney Disease, Anemia.

Is NCT01244763 still recruiting?

NCT01244763 is currently completed. Last updated 10 February 2022.

Are results published for NCT01244763?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-02-10 · How we verify

NCT01244763

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Completed Phase 2 Results posted Last updated 10 February 2022

What this trial tests

Phase 2 trial testing Roxadustat in Chronic Kidney Disease in 145 participants. Completed in 13 June 2012.

Timeline

29 October 2010

Primary endpoint
13 June 2012

13 June 2012

Quick facts

Lead sponsor	Kyntra Bio
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	145
Start date	29 October 2010
Primary completion	13 June 2012
Estimated completion	13 June 2012
Sites	38 locations across Puerto Rico, United States

Drugs / interventions tested

Roxadustat (ROXADUSTAT) — full drug profile →

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Anemia — all drugs for Anemia →

Sponsor

Kyntra Bio — full company profile →

Who can join

Adults 18 to 75, any sex, with Chronic Kidney Disease or Anemia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number (%) of Participants With an Hb Response by Week 17 Primary · Up to Week 17

An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	19
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	24
Cohort C: Roxadustat at 50 mg TIW	21
Cohort D: Roxadustat at 100 mg TIW	23
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	23
Cohort F: Roxadustat at 70 mg BIW Then QW	21

Number (%) of Participants With an Hb Response by Weeks 5, 9, 13, 17, 21, and 25 Secondary · Up to Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)

An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.

Week 5

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	15
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	14
Cohort C: Roxadustat at 50 mg TIW	3
Cohort D: Roxadustat at 100 mg TIW	13
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	9
Cohort F: Roxadustat at 70 mg BIW Then QW	9

Week 9

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	18
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	21
Cohort C: Roxadustat at 50 mg TIW	12
Cohort D: Roxadustat at 100 mg TIW	20
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	18
Cohort F: Roxadustat at 70 mg BIW Then QW	13

Week 13

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	18
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	23
Cohort C: Roxadustat at 50 mg TIW	15
Cohort D: Roxadustat at 100 mg TIW	21
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	20
Cohort F: Roxadustat at 70 mg BIW Then QW	16

Week 17

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	19
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	24
Cohort C: Roxadustat at 50 mg TIW	17
Cohort D: Roxadustat at 100 mg TIW	22
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	23
Cohort F: Roxadustat at 70 mg BIW Then QW	20

Week 21

Group	Value	95% CI
Cohort C: Roxadustat at 50 mg TIW	19
Cohort D: Roxadustat at 100 mg TIW	22
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	23
Cohort F: Roxadustat at 70 mg BIW Then QW	21

Week 25

Group	Value	95% CI
Cohort C: Roxadustat at 50 mg TIW	21
Cohort D: Roxadustat at 100 mg TIW	23
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	23
Cohort F: Roxadustat at 70 mg BIW Then QW	21

Change From Baseline in Hb at Weeks 5, 9, 13, 17, 21, and 25 Secondary · Baseline, Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)

Baseline is defined as the mean of the last 3 available values predose.

Baseline

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	9.56	± 0.88
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	9.67	± 0.62
Cohort C: Roxadustat at 50 mg TIW	9.80	± 0.50
Cohort D: Roxadustat at 100 mg TIW	9.68	± 0.77
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	9.89	± 0.60
Cohort F: Roxadustat at 70 mg BIW Then QW	9.72	± 0.60

Change at Week 5

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	1.71	± 1.02
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	1.11	± 0.96
Cohort C: Roxadustat at 50 mg TIW	0.57	± 0.65
Cohort D: Roxadustat at 100 mg TIW	1.65	± 0.95
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	0.74	± 0.75
Cohort F: Roxadustat at 70 mg BIW Then QW	0.63	± 0.85

Change at Week 9

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	2.58	± 0.97
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	1.77	± 1.18
Cohort C: Roxadustat at 50 mg TIW	0.99	± 0.87
Cohort D: Roxadustat at 100 mg TIW	2.21	± 1.02
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1.67	± 0.98
Cohort F: Roxadustat at 70 mg BIW Then QW	0.89	± 1.23

Change at Week 13

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	2.46	± 0.93
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	2.06	± 1.07
Cohort C: Roxadustat at 50 mg TIW	1.26	± 1.09
Cohort D: Roxadustat at 100 mg TIW	2.17	± 1.19
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1.43	± 0.90
Cohort F: Roxadustat at 70 mg BIW Then QW	1.19	± 1.10

Change at Week 17

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	2.63	± 0.83
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	2.28	± 0.87
Cohort C: Roxadustat at 50 mg TIW	1.43	± 1.15
Cohort D: Roxadustat at 100 mg TIW	2.26	± 1.31
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1.50	± 0.73
Cohort F: Roxadustat at 70 mg BIW Then QW	1.46	± 1.23

Change at Week 21

Group	Value	95% CI
Cohort C: Roxadustat at 50 mg TIW	1.30	± 0.97
Cohort D: Roxadustat at 100 mg TIW	1.94	± 0.81
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1.19	± 1.08
Cohort F: Roxadustat at 70 mg BIW Then QW	1.79	± 0.77

Change at Week 25

Group	Value	95% CI
Cohort C: Roxadustat at 50 mg TIW	1.33	± 1.00
Cohort D: Roxadustat at 100 mg TIW	1.73	± 1.14
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1.28	± 1.08
Cohort F: Roxadustat at 70 mg BIW Then QW	1.51	± 1.06

Number (%) of Participants With Mean Hb Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28 Secondary · Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)

Participants can have a Hb value reported for more than 1 of the categories (11-12, 11-13, and 10.5-13 g/dL) during the week intervals since these categories are not mutually exclusive.

Weeks 5-8, HB Value of 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	4
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	11
Cohort C: Roxadustat at 50 mg TIW	7
Cohort D: Roxadustat at 100 mg TIW	8
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	10
Cohort F: Roxadustat at 70 mg BIW Then QW	7

Weeks 5-8, HB Value of 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	13
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	14
Cohort C: Roxadustat at 50 mg TIW	7
Cohort D: Roxadustat at 100 mg TIW	12
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	13
Cohort F: Roxadustat at 70 mg BIW Then QW	8

Weeks 5-8, HB Value of 10.5-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	16
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	18
Cohort C: Roxadustat at 50 mg TIW	14
Cohort D: Roxadustat at 100 mg TIW	16
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	17
Cohort F: Roxadustat at 70 mg BIW Then QW	13

Weeks 9-12, HB Value of 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	5
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	12
Cohort C: Roxadustat at 50 mg TIW	7
Cohort D: Roxadustat at 100 mg TIW	8
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	9
Cohort F: Roxadustat at 70 mg BIW Then QW	6

Weeks 9-12, HB Value of 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	13
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	18
Cohort C: Roxadustat at 50 mg TIW	9
Cohort D: Roxadustat at 100 mg TIW	16
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	12
Cohort F: Roxadustat at 70 mg BIW Then QW	10

Weeks 9-12, HB Value of 10.5-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	14
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	21
Cohort C: Roxadustat at 50 mg TIW	16
Cohort D: Roxadustat at 100 mg TIW	17
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	16
Cohort F: Roxadustat at 70 mg BIW Then QW	15

Weeks 9-16, HB Value of 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	6
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	11
Cohort C: Roxadustat at 50 mg TIW	8
Cohort D: Roxadustat at 100 mg TIW	8
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	11
Cohort F: Roxadustat at 70 mg BIW Then QW	7

Weeks 9-16, HB Value of 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	12
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	19
Cohort C: Roxadustat at 50 mg TIW	11
Cohort D: Roxadustat at 100 mg TIW	16
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	14
Cohort F: Roxadustat at 70 mg BIW Then QW	11

Number (%) of Participants With 2 Consecutive Hb Values Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 13-16, 9-16, 17-20, 17-24, 21-24, and 25-28 Secondary · Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)

Weeks 5-8, Hb Value of 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	4
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	11
Cohort C: Roxadustat at 50 mg TIW	5
Cohort D: Roxadustat at 100 mg TIW	9
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	8
Cohort F: Roxadustat at 70 mg BIW Then QW	4

Weeks 5-8, Hb Value of 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	13
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	14
Cohort C: Roxadustat at 50 mg TIW	8
Cohort D: Roxadustat at 100 mg TIW	12
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	12
Cohort F: Roxadustat at 70 mg BIW Then QW	6

Weeks 5-8, Hb Value of 10.5-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	15
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	17
Cohort C: Roxadustat at 50 mg TIW	14
Cohort D: Roxadustat at 100 mg TIW	16
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	16
Cohort F: Roxadustat at 70 mg BIW Then QW	13

Weeks 9-12, Hb Value of 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	5
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	12
Cohort C: Roxadustat at 50 mg TIW	7
Cohort D: Roxadustat at 100 mg TIW	8
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	10
Cohort F: Roxadustat at 70 mg BIW Then QW	8

Weeks 9-12, Hb Value of 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	12
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	17
Cohort C: Roxadustat at 50 mg TIW	10
Cohort D: Roxadustat at 100 mg TIW	16
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	12
Cohort F: Roxadustat at 70 mg BIW Then QW	11

Weeks 9-12, Hb Value of 10.5-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	14
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	21
Cohort C: Roxadustat at 50 mg TIW	16
Cohort D: Roxadustat at 100 mg TIW	18
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	17
Cohort F: Roxadustat at 70 mg BIW Then QW	15

Weeks 9-16, Hb Value of 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	8
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	16
Cohort C: Roxadustat at 50 mg TIW	10
Cohort D: Roxadustat at 100 mg TIW	10
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	15
Cohort F: Roxadustat at 70 mg BIW Then QW	11

Weeks 9-16, Hb Value of 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	14
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	22
Cohort C: Roxadustat at 50 mg TIW	13
Cohort D: Roxadustat at 100 mg TIW	20
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	18
Cohort F: Roxadustat at 70 mg BIW Then QW	15

Number (%) of Participants Who Achieve Maximum Hb Between 11-12, 11-13, and 10.5-13 g/dL by Weeks 5, 9, 13, 17, 21, and 25 Secondary · Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)

Participants can have a Hb value for the same category (11-12, 11-13, or 10.5-13 g/dL) reported for multiple weeks.

Hb Value of 11-12 g/dL by Week 5

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	9
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	11
Cohort C: Roxadustat at 50 mg TIW	5
Cohort D: Roxadustat at 100 mg TIW	8
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	11
Cohort F: Roxadustat at 70 mg BIW Then QW	10

Hb Value of 11-12 g/dL by Week 9

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	11
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	16
Cohort C: Roxadustat at 50 mg TIW	11
Cohort D: Roxadustat at 100 mg TIW	11
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	15
Cohort F: Roxadustat at 70 mg BIW Then QW	14

Hb Value of 11-12 g/dL by Week 13

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	11
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	19
Cohort C: Roxadustat at 50 mg TIW	14
Cohort D: Roxadustat at 100 mg TIW	13
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	17
Cohort F: Roxadustat at 70 mg BIW Then QW	17

Hb Value of 11-12 g/dL by Week 17

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	12
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	20
Cohort C: Roxadustat at 50 mg TIW	16
Cohort D: Roxadustat at 100 mg TIW	14
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	17
Cohort F: Roxadustat at 70 mg BIW Then QW	20

Hb Value of 11-12 g/dL by Week 21

Group	Value	95% CI
Cohort C: Roxadustat at 50 mg TIW	17
Cohort D: Roxadustat at 100 mg TIW	15
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	19
Cohort F: Roxadustat at 70 mg BIW Then QW	22

Hb Value of 11-12 g/dL by Week 25

Group	Value	95% CI
Cohort C: Roxadustat at 50 mg TIW	21
Cohort D: Roxadustat at 100 mg TIW	18
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	20
Cohort F: Roxadustat at 70 mg BIW Then QW	22

Hb Value of 11-13 g/dL by Week 5

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	16
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	14
Cohort C: Roxadustat at 50 mg TIW	6
Cohort D: Roxadustat at 100 mg TIW	14
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	13
Cohort F: Roxadustat at 70 mg BIW Then QW	10

Hb Value of 11-13 g/dL by Week 9

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	18
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	21
Cohort C: Roxadustat at 50 mg TIW	14
Cohort D: Roxadustat at 100 mg TIW	19
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	18
Cohort F: Roxadustat at 70 mg BIW Then QW	14

Number (%) of Participants With Maximum Hb <11, >12, >13, and >14 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28 Secondary · Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)

Weeks 5-8, Hb Value of <11 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	6
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	9
Cohort C: Roxadustat at 50 mg TIW	10
Cohort D: Roxadustat at 100 mg TIW	5
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	6
Cohort F: Roxadustat at 70 mg BIW Then QW	13

Weeks 5-8, Hb Value of 12-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	10
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	6
Cohort C: Roxadustat at 50 mg TIW	4
Cohort D: Roxadustat at 100 mg TIW	6
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	4
Cohort F: Roxadustat at 70 mg BIW Then QW	3

Weeks 5-8, Hb Value of 13-14 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	2
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	1
Cohort C: Roxadustat at 50 mg TIW	0
Cohort D: Roxadustat at 100 mg TIW	3
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1
Cohort F: Roxadustat at 70 mg BIW Then QW	0

Weeks 5-8, Hb Value of >14 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	1
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0
Cohort C: Roxadustat at 50 mg TIW	0
Cohort D: Roxadustat at 100 mg TIW	1
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	0
Cohort F: Roxadustat at 70 mg BIW Then QW	0

Weeks 9-12, Hb Value of <11 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	4
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	2
Cohort C: Roxadustat at 50 mg TIW	9
Cohort D: Roxadustat at 100 mg TIW	4
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	7
Cohort F: Roxadustat at 70 mg BIW Then QW	11

Weeks 9-12, Hb Value of 12-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	5
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	9
Cohort C: Roxadustat at 50 mg TIW	4
Cohort D: Roxadustat at 100 mg TIW	8
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	6
Cohort F: Roxadustat at 70 mg BIW Then QW	6

Weeks 9-12, Hb Value of 13-14 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	7
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	1
Cohort C: Roxadustat at 50 mg TIW	1
Cohort D: Roxadustat at 100 mg TIW	3
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	3
Cohort F: Roxadustat at 70 mg BIW Then QW	0

Weeks 9-12, Hb Value of >14 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	2
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	1
Cohort C: Roxadustat at 50 mg TIW	0
Cohort D: Roxadustat at 100 mg TIW	2
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	0
Cohort F: Roxadustat at 70 mg BIW Then QW	0

Median Time to Hb Response: Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL Secondary · Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C-F)

Median time to response was estimated using Kaplan Meier method, Cohort A and B censored at Week 17, Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	28.0	28.0 – 56.0
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	28.0	28.0 – 56.0
Cohort C: Roxadustat at 50 mg TIW	48.9	28.0 – 56.0
Cohort D: Roxadustat at 100 mg TIW	28.0	28.0 – 56.0
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	35.0	28.0 – 56.0
Cohort F: Roxadustat at 70 mg BIW Then QW	56.0	28.0 – 56.0

Median Initial Hb Responsive Time: Time to Initial Hb Increase ≥1.0 g/dL From Baseline Secondary · Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C, D, E, and F)

Median time to response was estimated using Kaplan Meier method; Cohort A and B censored at Week 17 and Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	21.0	21.0 – 42.0
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	21.6	21.0 – 42.0
Cohort C: Roxadustat at 50 mg TIW	42.0	21.0 – 42.0
Cohort D: Roxadustat at 100 mg TIW	21.0	21.0 – 42.0
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	35.0	21.0 – 42.0
Cohort F: Roxadustat at 70 mg BIW Then QW	42.0	21.0 – 42.0

Median Initial Hb Responsive Dose: Dose at Which Initial Hb Increases to ≥1.0 g/dL From Baseline Secondary · Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C-F)

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	2.30	0.6 – 6.4
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	2.50	1.4 – 4.4
Cohort C: Roxadustat at 50 mg TIW	2.32	0.7 – 6.6
Cohort D: Roxadustat at 100 mg TIW	2.36	0.8 – 6.5
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	1.96	0.5 – 4.9
Cohort F: Roxadustat at 70 mg BIW Then QW	1.61	0.8 – 4.6

Change in Hb After Reaching a Hb Response of ≥11.0 g/dL and an Increase in Hb by ≥1.0 g/dL by Week Secondary · Cohorts A and B: Weekly through Week 16 (end of treatment), Week 18 (2 weeks posttreatment), and Week 20 (4 weeks posttreatment); Cohorts C-F: Weekly through Week 24 (end of treatment), Week 26 (2 weeks posttreatment), and Week 28 (4 weeks posttreatment)

Hb at Response Timepoint

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	11.49	± 0.414
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	11.40	± 0.289
Cohort C: Roxadustat at 50 mg TIW	11.32	± 0.360
Cohort D: Roxadustat at 100 mg TIW	11.47	± 0.430
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	11.62	± 0.543
Cohort F: Roxadustat at 70 mg BIW Then QW	11.43	± 0.348

Change after 1 week

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	0.30	± 0.579
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.03	± 0.562
Cohort C: Roxadustat at 50 mg TIW	-0.18	± 0.854
Cohort D: Roxadustat at 100 mg TIW	0.18	± 0.570
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	-0.26	± 0.709
Cohort F: Roxadustat at 70 mg BIW Then QW	-0.23	± 0.394

Change after 2 weeks

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	0.46	± 0.685
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.05	± 0.634
Cohort C: Roxadustat at 50 mg TIW	-0.22	± 0.868
Cohort D: Roxadustat at 100 mg TIW	0.41	± 0.678
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	-0.34	± 0.720
Cohort F: Roxadustat at 70 mg BIW Then QW	-0.21	± 0.707

Change after 3 weeks

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	0.67	± 0.635
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.19	± 0.720
Cohort C: Roxadustat at 50 mg TIW	-0.02	± 0.842
Cohort D: Roxadustat at 100 mg TIW	0.44	± 0.873
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	-0.31	± 0.934
Cohort F: Roxadustat at 70 mg BIW Then QW	-0.25	± 0.682

Change after 4 weeks

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	0.81	± 0.642
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.17	± 0.968
Cohort C: Roxadustat at 50 mg TIW	0.06	± 0.767
Cohort D: Roxadustat at 100 mg TIW	0.61	± 0.859
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	-0.18	± 1.080
Cohort F: Roxadustat at 70 mg BIW Then QW	-0.24	± 0.794

Change after 5 weeks

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	0.99	± 0.705
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.20	± 1.004
Cohort C: Roxadustat at 50 mg TIW	-0.07	± 0.701
Cohort D: Roxadustat at 100 mg TIW	0.65	± 0.883
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	-0.05	± 1.295
Cohort F: Roxadustat at 70 mg BIW Then QW	0.13	± 0.752

Change after 6 weeks

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	1.01	± 0.999
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.23	± 0.931
Cohort C: Roxadustat at 50 mg TIW	0.02	± 0.821
Cohort D: Roxadustat at 100 mg TIW	0.67	± 0.799
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	0.10	± 1.274
Cohort F: Roxadustat at 70 mg BIW Then QW	-0.01	± 0.937

Change after 7 weeks

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	0.97	± 0.874
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	0.21	± 0.860
Cohort C: Roxadustat at 50 mg TIW	0.40	± 0.876
Cohort D: Roxadustat at 100 mg TIW	0.87	± 0.882
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	-0.21	± 1.255
Cohort F: Roxadustat at 70 mg BIW Then QW	0.03	± 0.830

Mean Hb Values From Participants Who Reached Hb >11.0 g/dL in the Hb 11-12, 11-13, and 10.5-13 g/dL Categories Secondary · Cohorts A and B: Weekly through Week 16 (end of treatment [EoT]) and Week 20 (Follow up [4 weeks posttreatment]); Cohorts C-F: Weekly through Week 24 (EoT) and Week 28 (Follow up [4 weeks posttreatment])

After Response through EoT, Hb Category <11 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	11.50	± 25.937
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	18.75	± 27.254
Cohort C: Roxadustat at 50 mg TIW	35.48	± 32.727
Cohort D: Roxadustat at 100 mg TIW	14.03	± 18.311
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	38.32	± 30.175
Cohort F: Roxadustat at 70 mg BIW Then QW	32.56	± 33.384

After Response through EoT, Hb Category 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	31.46	± 30.410
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	48.86	± 26.771
Cohort C: Roxadustat at 50 mg TIW	46.67	± 29.540
Cohort D: Roxadustat at 100 mg TIW	41.54	± 26.619
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	44.17	± 22.858
Cohort F: Roxadustat at 70 mg BIW Then QW	47.00	± 27.692

After Response through EoT, Hb Category 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	66.73	± 27.453
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	76.05	± 26.577
Cohort C: Roxadustat at 50 mg TIW	62.10	± 31.528
Cohort D: Roxadustat at 100 mg TIW	74.96	± 24.078
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	56.92	± 27.338
Cohort F: Roxadustat at 70 mg BIW Then QW	64.39	± 32.083

After Response through EoT, Hb Category 10.5-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	76.80	± 23.899
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	87.20	± 20.118
Cohort C: Roxadustat at 50 mg TIW	82.69	± 25.854
Cohort D: Roxadustat at 100 mg TIW	83.50	± 21.354
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	79.01	± 23.045
Cohort F: Roxadustat at 70 mg BIW Then QW	83.97	± 26.219

In Follow Up, Hb Category <11 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	16.67	± 34.300
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	35.71	± 42.258
Cohort C: Roxadustat at 50 mg TIW	54.76	± 41.547
Cohort D: Roxadustat at 100 mg TIW	47.83	± 43.896
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	57.50	± 43.755
Cohort F: Roxadustat at 70 mg BIW Then QW	50.00	± 44.096

In Follow Up, Hb Category 11-12 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	30.56	± 38.877
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	40.48	± 40.679
Cohort C: Roxadustat at 50 mg TIW	40.48	± 40.679
Cohort D: Roxadustat at 100 mg TIW	41.30	± 38.883
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	30.00	± 37.697
Cohort F: Roxadustat at 70 mg BIW Then QW	47.37	± 42.406

In Follow Up, Hb Category 11-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	69.44	± 42.492
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	59.52	± 40.679
Cohort C: Roxadustat at 50 mg TIW	45.24	± 41.547
Cohort D: Roxadustat at 100 mg TIW	52.17	± 43.896
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	42.50	± 43.755
Cohort F: Roxadustat at 70 mg BIW Then QW	50.00	± 44.096

In Follow Up, Hb Category 10.5-13 g/dL

Group	Value	95% CI
Cohort A: Roxadustat Tiered, Weight Based Dosing TIW	75.00	± 39.295
Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW	83.33	± 32.914
Cohort C: Roxadustat at 50 mg TIW	66.67	± 36.515
Cohort D: Roxadustat at 100 mg TIW	71.74	± 39.388
Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW	65.00	± 43.225
Cohort F: Roxadustat at 70 mg BIW Then QW	73.68	± 34.835

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline up to Week 28 (end of study). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort A: Roxadustat Tiered, Weight Based Dosing TIW

Serious: 3/24 (13%)

Deaths: —

Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW

Serious: 4/24 (17%)

Deaths: —

Cohort C: Roxadustat at 50 mg TIW

Serious: 4/24 (17%)

Deaths: —

Cohort D: Roxadustat at 100 mg TIW

Serious: 4/24 (17%)

Deaths: —

Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW

Serious: 10/24 (42%)

Deaths: —

Cohort F: Roxadustat at 70 mg BIW Then QW

Serious: 10/25 (40%)

Deaths: —

Serious adverse events (40 terms)

Reaction	System	Cohort A: Roxadustat Tiere…	Cohort B: Roxadustat Tiere…	Cohort C: Roxadustat at 50…	Cohort D: Roxadustat at 10…	Cohort E: Roxadustat Tiere…	Cohort F: Roxadustat at 70…
Cardiac Failure Congestive	Cardiac disorders	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—
Cardio-Respiratory Arrest	Cardiac disorders	—	—	—	—	—	—
Acute Myocardial Infarction	Cardiac disorders	—	—	—	—	—	—
Atrial Fibrillation	Cardiac disorders	—	—	—	—	—	—
Myocardial Infarction	Cardiac disorders	—	—	—	—	—	—
Renal Failure Acute	Renal and urinary disorders	—	—	—	—	—	—
Renal Failure Chronic	Renal and urinary disorders	—	—	—	—	—	—
Renal Impairment	Renal and urinary disorders	—	—	—	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal Pain Lower	Gastrointestinal disorders	—	—	—	—	—	—
Diabetic Gastroparesis	Gastrointestinal disorders	—	—	—	—	—	—
Haematemesis	Gastrointestinal disorders	—	—	—	—	—	—
Pancreatitis Acute	Gastrointestinal disorders	—	—	—	—	—	—
Abscess	Infections and infestations	—	—	—	—	—	—
Bronchopneumonia	Infections and infestations	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Diabetic Ketoacidosis	Metabolism and nutrition disorders	—	—	—	—	—	—
Hyperglycaemic Hyperosmolar Nonketotic Syndrome	Metabolism and nutrition disorders	—	—	—	—	—	—
Acute Respiratory Failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Pulmonary Embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Pulmonary Oedema	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—

Other adverse events (11 terms — click to expand)

Reaction	System	Cohort A: Roxadustat Tiere…	Cohort B: Roxadustat Tiere…	Cohort C: Roxadustat at 50…	Cohort D: Roxadustat at 10…	Cohort E: Roxadustat Tiere…	Cohort F: Roxadustat at 70…
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Oedema Peripheral	General disorders	—	—	—	—	—	—
Urinary Tract Infection	Infections and infestations	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—

Most-reported serious reactions: Cardiac Failure Congestive, Cellulitis, Cardio-Respiratory Arrest, Acute Myocardial Infarction, Atrial Fibrillation, Myocardial Infarction, Renal Failure Acute, Renal Failure Chronic.

Data from ClinicalTrials.gov NCT01244763 adverse events section.

Sponsor's own description

The primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R, Besarab A, Sun CH, Diamond SA, et al · · 2016 · cited 224× · PMID 27094610 · DOI 10.2215/cjn.06890615
Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin.
Hanna RM, Streja E, Kalantar-Zadeh K. · · 2021 · cited 114× · PMID 33123967 · DOI 10.1007/s12325-020-01524-6
Treatment of Renal Anemia with Roxadustat: Advantages and Achievement.
Li ZL, Tu Y, Liu BC. · · 2020 · cited 54× · PMID 32309288 · DOI 10.1159/000504850
Iron metabolism and management: focus on chronic kidney disease.
Agarwal AK. · · 2021 · cited 31× · PMID 33777495 · DOI 10.1016/j.kisu.2020.12.003
Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease.
Finkelstein FO, van Nooten F, Wiklund I, Trundell D, et al · · 2018 · cited 28× · PMID 29855366 · DOI 10.1186/s12955-018-0933-8
Challenging patient phenotypes in the management of anaemia of chronic kidney disease.
Pramod S, Goldfarb DS. · · 2021 · cited 7× · PMID 34331826 · DOI 10.1111/ijcp.14681
Whether Prolyl Hydroxylase Blocker-Roxadustat-In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
Grzeszczak W, Szczyra D, Śnit M. · · 2021 · cited 5× · PMID 33567688 · DOI 10.3390/ijerph18041612
Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.
Luo X, Li G, Yang H, Chen L, et al · · 2024 · cited 3× · PMID 38311719 · DOI 10.1186/s12882-024-03474-5

Verify or expand the search:

Other trials of Roxadustat

Trials testing the same drug.

NCT07268807 — Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease · not yet recruiting
NCT07162090 — Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients · Phase 4 · not yet recruiting
NCT05810311 — The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy · Phase 2 · not yet recruiting
NCT06903559 — Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients · Phase 1, PHASE2 · recruiting
NCT06917950 — Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients · Phase 1, PHASE2 · recruiting

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Other Kyntra Bio trials

Trials by the same sponsor.

NCT06842498 — A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Phase 2 · recruiting
NCT04621331 — Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD · Phase 3 · withdrawn
NCT05301517 — A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemothe · Phase 3 · completed
NCT04632940 — Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD · Phase 3 · terminated
NCT04419558 — Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01244763 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyntra Bio
Last refreshed: 10 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01244763.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01244763

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (40 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Roxadustat

Other recruiting trials for Chronic Kidney Disease

Other Kyntra Bio trials

Verify against primary sources